Princeton-based biopharmaceutical company Certara has agreed to acquire Analytica Laser, a London-based health research consultant that specializes in providing real-world data to research new medications and health technologies.
Terms weren’t disclosed.
Analytica Laser uses various quantitative methods and proprietary software to study and predict real-world outcomes for drug value assessment, pharmaco-epidemiology, pharmaco-economics, public health intelligence, and advice on pricing and market access strategy.
As part of the transaction, Analytica Laser Founder Dr. Lucien Abenhaim will join Certara as a scientific advisor. He has served as the General Director of Health, Chief Medical Officer, and head of all health organizations for the French Ministry of Health, and as member of the Executive Council of the World Health Organization.
Real world data – as opposed to clinical data – derives medical data from real world sources such as electronic health records, claims and billing data, product and disease registries and personal health applications. The U.S. Food and Drug Administration recently acknowledged the increasing role that real world data is playing in health care decisions and the approvals of new drugs.
Pharmaceutical companies have been lobbying the FDA to consider more real-world data when deciding to approve a drug, as a way to lessen the immense costs of conducting phase III clinical trials.